中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.022 seconds)

    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION
    5.
    发明申请
    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 审中-公开
    基于TnT的PAROXYSMAL ATRIAL FIBRILLATION的诊断

    公开(公告)号：US20150233946A1

    公开(公告)日：2015-08-20

    申请号：US14705528

    申请日：2015-05-06

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/68

    CPC classification number: G01N33/6887 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4712 ,  G01N2333/4737 ,  G01N2333/4745 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2800/326 ,  G01N2800/52

    Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

    Abstract translation: 本发明涉及一种诊断近期阵发性房颤的方法。 该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（ 来自受试者的样品中的胰岛素样生长因子结合蛋白7），以及由此确定的量与参考量（参考量）的比较。 此外，本发明涉及用抗凝治疗来鉴别受治疗者的方法。 进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING
    7.
    发明申请
    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING 有权

    公开(公告)号：US20220412991A1

    公开(公告)日：2022-12-29

    申请号：US17891458

    申请日：2022-08-19

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

    IPC: G01N33/68 ,  A61B5/055 ,  A61B8/08

    Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

    Assessing whether a subject shall be subjected to imaging based diagnostic
    8.
    发明授权
    Assessing whether a subject shall be subjected to imaging based diagnostic 有权

    公开(公告)号：US11454634B2

    公开(公告)日：2022-09-27

    申请号：US15911699

    申请日：2018-03-05

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

    IPC: G01N33/68 ,  A61B5/055 ,  A61B8/08

    Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION
    9.
    发明申请
    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 审中-公开
    基于TnT的PAROXYSMAL ATRIAL FIBRILLATION的诊断

    公开(公告)号：US20170074892A1

    公开(公告)日：2017-03-16

    申请号：US15359674

    申请日：2016-11-23

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/68

    CPC classification number: G01N33/6887 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4712 ,  G01N2333/4737 ,  G01N2333/4745 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2800/326 ,  G01N2800/52

    Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

    Abstract translation: 本发明涉及一种诊断近期阵发性房颤的方法。 该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（ 来自受试者的样品中的胰岛素样生长因子结合蛋白7），以及由此确定的量与参考量（参考量）的比较。 此外，本发明涉及用抗凝治疗来鉴别受治疗者的方法。 进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING
    10.
    发明申请
    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING 审中-公开
    鉴别患有异常分娩的患者

    公开(公告)号：US20150185230A1

    公开(公告)日：2015-07-02

    申请号：US14644695

    申请日：2015-03-11

    Applicant: Roche Diagnostics Operations, Inc

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

    IPC: G01N33/68 ,  A61B5/055 ,  A61B8/08

    CPC classification number: G01N33/6887 ,  A61B5/055 ,  A61B8/0883 ,  G01N33/82 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/4712 ,  G01N2333/50 ,  G01N2333/78 ,  G01N2800/32 ,  G01N2800/329 ,  G01N2800/50

    Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

    Abstract translation: 本发明涉及一种用于评估受试者是否应进行基于成像的诊断评估的方法。 该方法基于来自受试者的样品中心肌肌钙蛋白和/或成纤维细胞生长因子23（FGF-23）的量的测定，以及因此确定的量（s） 具有参考量（参考量）。 本发明还涉及一种用于执行评估受试者是否应进行基于成像的诊断评估的系统以及用于执行本文所公开的方法的试剂和试剂盒。 此外，本发明涉及一种用于预测死亡风险和/或心血管事件风险的方法。 还包括用于诊断具有保留的左心室射血的受试者的LVH的早期阶段的方法。

Patent Agency Ranking